pan-kras inhibitor bgb-53038
Generic: Pan-KRAS Inhibitor BGB-53038
pan-kras inhibitor bgb-53038: 1 clinical trial tracked.
pan-kras inhibitor bgb-53038 evidence translation
What we can confirm
1 tracked trial
No verified listed company relationship
What it means
AI will separate confirmed drug evidence from unknown company context.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about pan-kras inhibitor bgb-53038, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence0 indications · 1 study sponsors
Related indications
No linked indication is available.
Study sponsors
Clinical Trial Registry Records (1)
A Phase 1a/1b Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-53038, a Pan-KRAS Inhibitor, as Monotherapy or in Combinations in Patients With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplifications
Primary endpoint: Phase 1a: Number of Participants Experiencing Adverse Events (AEs)
InterventionalRandomizedopen47 enrolledStarted 2024-12Completion 2026-0417 sites · Australia, China, New Zealand, South Korea…BeOne Medicines